Capmatinib for MET Exon 14–Mutated or MET-Amplified NSCLC
Capmatinib for MET Exon 14–Mutated or MET-Amplified NSCLC
About this item
Full title
Capmatinib for MET Exon 14–Mutated or MET-Amplified NSCLC
Author / Creator
Publisher
Waltham: Massachusetts Medical Society
Journal title
NEJM journal watch. Oncology & hematology, 2020-09
Language
English
Formats
Publication information
Publisher
Waltham: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The MET-receptor inhibitor capmatinib demonstrated substantial antitumor activity in patients with advanced MET-dysregulated non–small-cell lung cancer.
Alternative Titles
Full title
Capmatinib for MET Exon 14–Mutated or MET-Amplified NSCLC
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2440839190
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2440839190
Other Identifiers
ISSN
2330-0426
How to access this item
Log in as a Library member
